iiinova — where your digital self keeps evolving

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 24/11/2025

We are absolutely thrilled to share that the OCEANIC-STROKE trial has successfully met its primary efficacy & safety endpoints. These landmark findings address a major unmet need in the ~5M people worldwide who have a new non-cardioembolic ischemic stroke each year. www.bayer.com/media/en-us/...

bayer.com

020

Reposted by Ashkan Shoamanesh

JAMA @jama.com · 24/04/2025

High lipoprotein(a) levels, defined as 50 mg/dL or greater, are associated with increased rates of atherosclerotic cardiovascular disease events and all-cause mortality. This JAMA Insights discusses lipoprotein(a). #MedSky ja.ma/42Ma9Wv

ja.ma

Lipoprotein(a)

This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.

0102

Reposted by Ashkan Shoamanesh

CanStroke Recovery Trials Platform @canstroke.bsky.social · 24/04/2025

Exciting News! 🚨 Save the Date for the 2026 Canadian Stroke Congress 🗻 Banff, Alberta 📅 May 23-26, 2026 More details coming soon at www.CanadianStroke.ca #CSC2026 #StrokeCongress26 #SavetheDate #StrokeRecovery #StrokeResearch

032

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 24/04/2025

The ICH-ADAPT2 trial results were just published in @jama.com Neurology. DWI lesions are observed in ~33% of patients with acute ICH. Our findings do not support a causal relationship between intensive BP lowering and DWI lesions in these patients. jamanetwork.com/journals/jam...

jamanetwork.com

Blood Pressure Lowering and Risk of Ischemic Lesions After Intracerebral Hemorrhage

This multicenter, randomized clinical trial examines whether systolic blood pressure reduction increases the incidence of lesions detected with diffusion-weighted imaging in adult patients with acute ...

000

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 24/04/2025

Thrilled to share that the OCEANIC-STROKE trial (NCT05686070) led by PHRI & Bayer AG, has successfully completed enrolment of over 12,300 participants with non-cardioembolic ischemic #stroke over a recruitment period of only 26-months! 🔗https://phri.ca/oceanicstroke/

121

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 08/03/2025

For those interested and who were unable to join us at @americanheart.bsky.social #ISC2025 please find the recording of our @medscape.com webinar on the rise of new anticoagulants for stroke prevention here: www.youtube.com/watch?v=D8f0... @macdeptmed.bsky.social

youtube.com

Staying Ahead in Stroke Prevention: The Rise of New Anticoagulation Approaches

YouTube video by Medscape

023

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 08/03/2025

Absolutely honoured to be delivering the inaugural Ralph Sacco Distinguished Lecture at the @universityofmiami.bsky.social 58th Neurology Update & Stroke Intensive Review. Huge thanks to Drs. Negar Asdaghi & Jose Romano for their generous invitation and gracious hospitality! @macdeptmed.bsky.social

013

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 09/02/2025

Congrats to Ken Butcher on successfully leading the ICH-ADAPT 2 RCT. Our results do not support the notion that BP lowering contributes to the majority of acute/subacute DWI lesions in patients with ICH. Alternative mechanisms need to be explored. #ISC2025 @ahascience.bsky.social

030

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 09/02/2025

For those who were unable to attend our update on best practices for managing ICH at #ISC2025, you can find the recording below: www.youtube.com/watch?v=PiCn... @christoslazaridis.bsky.social

youtube.com

CME at ISC 2025 - Best Practices for Managing Intracerebral Hemorrhage

YouTube video by CMEPlanet

021

Reposted by Ashkan Shoamanesh

American Heart Association Journals @ahajournals.bsky.social · 06/02/2025

AHA/ASA Journals are on the ground at #ISC25 Check out the latest at www.ahajournals.org/isc

023

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 23/01/2025

Should patients with #stroke and device-detected subclinical #AFib (SCAF) be treated with OAC? Our subgroup analyses of the ARTESIA RCT (@thelancet.bsky.social) provide novel insights indicating that OAC is beneficial in appropriately selected patients. www.thelancet.com/journals/lan...

021

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 18/01/2025

WSO (@worldstrokeorg.bsky.social) Global ICH Factsheet journals.sagepub.com/doi/full/10....

010

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 16/01/2025

Thrilled to announce that the #EnrichAF randomized trial completed enrolment of 948 patients in Q4 2024. So grateful for the efforts of our global colleagues on reaching this milestone, who persevered despite many challenges along the way. Follow-up is due to complete in Q1 2026. Stay tuned!

011

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 31/12/2024

See our recent @worldstrokeorg.bsky.social scientific statement on secondary #stroke prevention in patients w #Afib. Big thanks Dr. Luciano Sposato for taking on the lion's share of work for this important piece. @macdeptmed.bsky.social journals.sagepub.com/doi/10.1177/...

journals.sagepub.com

010

Reposted by Ashkan Shoamanesh

CanVECTOR Network @canvector.bsky.social · 18/12/2024

🎉 Exciting News! 🎉 We are thrilled to announce that Dr. Deborah Siegal has been appointed as the next Co-Director of CanVECTOR (joining Co-Director Dr. Grégoire Le Gal), starting April 1, 2025! Learn more: 🔗 buff.ly/4gHeS1a #Research #Thrombosis #VTE

062

Ashkan Shoamanesh @ash-shoamanesh.bsky.social · 18/12/2024

Kudos to Dr. Lauren Mai from @westernu.bsky.social on leading this insightful narrative review outlining the protracted recovery trajectory of patients with ICH. www.ahajournals.org/doi/10.1161/... @macdeptmed.bsky.social @harvardmed.bsky.social @ahajournals.bsky.social @ahascience.bsky.social

ahajournals.org

American Heart Association Journals

013